US20020032170A1 - Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same - Google Patents

Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same Download PDF

Info

Publication number
US20020032170A1
US20020032170A1 US09841179 US84117901A US2002032170A1 US 20020032170 A1 US20020032170 A1 US 20020032170A1 US 09841179 US09841179 US 09841179 US 84117901 A US84117901 A US 84117901A US 2002032170 A1 US2002032170 A1 US 2002032170A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
glucan
soluble
neutral
β
ml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09841179
Inventor
Spiros Jamas
D. Easson
Gary Ostroff
Original Assignee
Spiros Jamas
Easson D. Davidson
Ostroff Gary R.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/473The waterborne disease being caused by a bacteria the bacteria being Escherichia coli, i.e. E. coli Infection

Abstract

The present invention relates to neutral, aqueous soluble β-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel β-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble β-glucan preparation has a high affinity for the β-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble β-glucan of this invention neither induces nor primes IL-1β, and TNFα production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble β-glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1β, TNFα) that can cause detrimental side effects, such as fever and inflammation.

Description

    BACKGROUND OF THE INVENTION
  • [0001]
    In the early 1960's, zymosan, a crude insoluble yeast extract prepared by boiling yeast before and after trypsin treatment, was noted to produce marked hyperplasia and functional stimulation of the raticuloendothelial system in rodents. In animal studies; zymosan preparations were shown to inactivate complement component C3, to enhance antibody formation, to promote survival following irradiation, to increase resistance to bacterial infections, to inhibit tumor development, to promote graft rejection, and to inhibit dietary-induced hypercholesterolemia and cholesterosis. Zymosan was shown to consist of polysacoharides, proteins, fats, and inorganic elements; however, subsequent studies identified the active components of the yeast cell wall as a pure polysaccharide, specifically β-glucan. In conventional nomenclature, the polysaccharide β-glucan is known as poly-(1-6)-β-O-glucopyranosyl-(1-3)-β-D-glucopyranose (PGG). Repetition of biological assays with β-glucan indicated that most of the above functional activities identified with zymosan were retained by the purified β-glucan preparation.
  • [0002]
    The properties of β-glucan are quite similar to those of endotoxin in increasing nonspecific immunity and resistance to infection. The activities of β-glucan as an immune adjuvant and hemopoietic stimulator compare to those of more complex biological response modifiers (BRMs), such as bacillus Calmette-Guerin (BCG) and Corynebacterium parvum. The functional activities of yeast β-glucan are also comparable to those structurally similar carbohydrate polymers isolated from fungi and plants. These higher molecular weight (1-3)-β-D-glucans such as schizophyllan, lentinan, krestin, grifolan, and pachyman exhibit similar immunomodulatory activities. A common mechanism shared by all these β-glucan preparations is their stimulation of cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF). Lentinan has been extensively investigated for its antitumor properties, both in animal models at 1 mg/kg for 10 days and in clinical trials since the late 1970's in Japan for advanced or recurrent malignant lymphoma and colorectal, mammary, lung and gastric cancers. In cancer chemotherapy, lentinan has been administered at 0.5-5 mg/day, intramuscularly (I. M.) or intravenously (I. V.), two or three times per week alone, or in combination with antineoplastic drugs. In addition to the activities ascribed to yeast glucans, studies suggest lentinan acts as a T-cell immunopotentiator, inducing cytotoxic activities, including production of interleukins 1 and 3 and colony-stimulating factors (CSF). (Chihara et al., 1989, Int. J. Immunotherapy, 4:145-154; Hamuro and Chihara, In Lentinan, An Immunopotentiator)
  • [0003]
    Various preparations of both particulate and soluble β-glucans have been tested in animal models to evaluate biological activities. The use of soluble and insoluble β-glucans alone or as vaccine adjuvants for viral and bacterial antigens has been shown in animal models to markedly increase resistance to a variety of bacterial, fungal, protozoan and viral infections. The hemopoietic effects of β-glucan have been correlated with increased peripheral blood leukocyte counts and bone marrow and splenic cellularity, reflecting increased numbers of granulocyte-macrophage progenitor cells, splenic pluripotent stem cells, and erythroid progenitor cells, as well as, increased serum levels of granulocyte-monocyte colony-stimulating factor (GM-CSF). Furthermore, the hemopoietic and anti-infective effects of β-glucan were active in cyclophosphamide-treated immunosuppressed animals. β-glucan was shown to be beneficial in animal models of trauma, wound healing and tumorigenesis. However, various insoluble and soluble preparations of β-glucan differed significantly ink biological specificity and potency, with effective dosages varying from 25-to 500 mg/kg intravenously or intraperitoneally (I. P.) in models for protection against infection and for hemopoiesis. Insoluble preparations demonstrated undesirable toxicological properties manifested by hepatosplenomegaly and granuloma formation. Clinical interest was focused on a soluble glucan preparation which would retain biological activity yet yield negligible toxicity when administered systemically. Chronic systemic administration of a soluble phosphorylated glucan over a wide range of doses (40-1000 mg/kg) yielded negligible toxicity in animals (DiLuzio et al., 1979, lnt. J. of Cancer, 24:773-779; DiLuzio, U.S. Pat. No. 4,739,046).
  • [0004]
    The molecular mechanism of action of β-glucan has been elucidated by the demonstration of specific β-glucan receptor binding sites on the cell membranes of human neutrophils and macrophages. Mannans, galactans, α(1-4)-linked glucose polymers and β(1-4)-linked glucose polymers have no avidity for this receptor. These β-glucan binding sites are opsonin-independent phagocytic receptors for particulate activators of the alternate complement pathway, similar to Escherichia coli lipopolysaccharide (LPS) and some animal red blood cells. Ligand binding to the β-glucan receptor, in the absence of antibody, results in complement activation, phagocytosis, lysosomal enzyme release, and prostaglandin, thromboxane and leukotriene generation; thereby increasing nonspecific resistance to infection. However, soluble β-glucan preparations described in the prior art demonstrated stimulation of cytokines. Increases in plasma and splenic levels of interleukins 1 and 2 (IL-1, IL-2) in addition to TNF were observed in vivo and corresponded to induction of the synthesis of these cytokines in vitro. (See Sherwood et al., 1987, Int. J. Immunopharmac., 9:261-267 (enhancement of IL-1 and IL-2 levels in rats injected with soluble glucan); Williams et al., 1988, Int. J. Immunopharmac., 10:405-414 (systemic administration of soluble glucan to AIDS patients increased IL-1 and IL-2 levels which were accompanied by chills and fever); Browder et al., 1990, Ann. Sure, 211:605-613 (glucan administration to trauma patients increased serum IL-1 levels, but not TNF levels); Adachi et al., 1990, Chem. Pharm. Bull., 38:988-992 (chemically cross-linked β(1-3) glucans induced IL-1 production in mice).)
  • [0005]
    Interleukin-1 is a primary immunologic mediator involved in cellular defense mechanisms. Numerous studies have been carried out on the application of IL-1 to enhance non-specific resistance to infection in a variety of clinical states. Pomposelli et al., J. Parent. Ent. Nutr. 12(2):212-218, (1988). The major problem associated with the excessive stimulation or exogenous administration of IL-1 and other cellular mediators in humans is toxicity and side effects resulting from the disruption of the gentle balance of the immunoregulatory network. Fauci et al., Ann. Int. Med., 106:421-433 (1987). IL-1 is an inflammatory cytokine that has been shown to adversely affect a variety of tissues and organs. For instance, recombinant IL-1 has been shown to cause death, hypotensive shock, leukopenia, thrombocytopenia, anemia and lactic acidosis. In addition, IL-1 induces sodium excretion, anorexia, slow wave sleep, bone resorption, decreased pain threshold and expression of many inflammatory-associated cytokines. It is also toxic to the insulin secreting beta cells of the pancreas. Patients suffering from a number of inflammatory diseases have elevated levels of IL-1 in their systems. Administration of agents that enhance further IL-1 production only exacerbate these inflammatory conditions.
  • [0006]
    Tumor necrosis factor is also involved in infection, inflammation and cancer. Small amounts of TNF release growth factors while in larger amounts, TNF can cause septic shock, aches, pains, fever, clotting of blood, degradation of bone and stimulation of white blood cells and other immune defenses.
  • SUMMARY OF THE INVENTION
  • [0007]
    The present invention relates to neutral soluble β-glucans which enhance a host's immune defense mechanisms to infection but do not induce an inflammatory response, to preparations containing the neutral soluble β-glucans, and to a novel manufacturing process therefor. In the present method, soluble glucan which induces cytokine production is processed through a unique series of acid, alkaline and neutral treatment steps to yield a conformationally pure neutral soluble glucan preparation with unique biological properties. The neutral soluble glucan preparation retains a specific subset of immunological properties common to β-glucans but uniquely does not induce the production of IL-1 and TNF in vitro or in vivo. Throughout this specification, unless otherwise indicated, the expressions “neutral soluble glucan” and “neutral soluble β-glucan” refer to the composition prepared as described in Example 1.
  • [0008]
    The neutral soluble glucan preparation is produced by treating insoluble glucan with acid to produce a water soluble glucan, dissociating the native conformations of the soluble glucan at alkaline pH, purifying the desired molecular weight fraction at alkaline pH, re-annealing the dissociated glucan fraction under controlled conditions of time, temperature and pH to form a unique triple helicaal conformation, and further purifying under neutral pH to remove single helix and aggregated materials to yield a conformationally pure, neutral, water soluble, underivatized glucan which has a unique biological profile.
  • [0009]
    The neutral soluble glucan preparation has a high affinity for the β-glucan receptor of human monocytes and retains two primary biological activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes mononuclear cells to increase IL-1 and TNF production in vitro and in vivo.
  • [0010]
    The neutral soluble glucan preparation is appropriate for parenteral (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), topical, oral or intranasal administration to humans and animals as an anti-infective to combat infection associated with burns, surgery, chemotherapy, bone marrow disorders and other conditions in which the immune system may be compromised. Neutral soluble glucan produced by the present method can be maintained in a clear solution and equilibrated in a pharmaceutically acceptable carrier. Safe and efficacious preparations of the neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1 and TNF) that can cause detrimental side effects, such as fever and inflammation.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0011]
    [0011]FIG. 1 shows the general structure of neutral soluble glucan as being a linear β(1-3)-linked glucose polymer having periodic branching via a single β(1-6)-linked glucose moiety.
  • [0012]
    [0012]FIG. 2 shows a gel permeation chromatogram (pH 7) of soluble glucan which has not been purified by alkali dissociation and re-annealing. The chromatogram shows three species, referred to herein as high molecular weight aggregate (Ag), Peak A and Peak B (single helix glucan).
  • [0013]
    [0013]FIG. 3 is a chromatogram obtained for the neutral soluble glucan by gel permeation chromatography. The solid line represents the neutral soluble glucan at pH 7 and the broken line represents the neutral soluble glucan at pH 13.
  • [0014]
    [0014]FIG. 4 is a chromatogram obtained for the single helix β-glucan (Peak B) by gel permeation chromatography. The solid line represents Peak B at pH 7 and the broken line represents Peak B at pH 13.
  • [0015]
    [0015]FIG. 5 shows the change in serum IL-1 levels, over time, taken from patients intravenously infused with placebo (broken line) or neutral soluble glucan (solid line).
  • [0016]
    [0016]FIG. 6 shows the change in serum TNF levels, over time, taken from patients intravenously infused with lacebo (broken line) or neutral soluble glucan (solid line).
  • [0017]
    [0017]FIG. 7 is a diagram representing peripheral blood counts from irradiated mice following administration of neutral soluble glucan.
  • [0018]
    [0018]FIG. 8 is a diagram representing platelet cell counts from cisplatin-treated mice following administration of neutral soluble glucan.
  • DETAILED DESCRIPTION OF INVENTION
  • [0019]
    The invention relates to a neutral soluble β-glucan polymer that can bind to the β-glucan receptor and activate only a desired subset of immune responses. The terms “neutral soluble β-glucan” and “neutral soluble glucan”, unless otherwise specified, refer to the composition prepared as described in Example 1.
  • [0020]
    This neutral soluble β-glucan has been shown to increase the number of neutrophils and monocytes as well as their direct infection fighting activity (phagocytosis and microbial killing). However, the neutral soluble β-glucan does not stimulate the production of biochemical mediators, such as IL-1 and TNF, that can cause detrimental side effects such as high fever, inflammation, wasting disease and organ failure. These advantageous properties make neutral soluble glucan preparations of this invention useful in the prevention and treatment of infection because they selectively activate only those components of the immune system responsible for the initial response to infection, without stimulating the release of certain biochemical mediators that can cause adverse side effects. The solution containing the neutral soluble β-glucan also lacks the toxicity common to many immunomodulators.
  • [0021]
    The neutral soluble β-glucans of this invention are composed of glucose monomers organized as a β(1-3) linked glucopyranose backbone with periodic branching via β(1-6) glycosidic linkages. The neutral soluble glucan preparations contain glucans, which have not been substantially modified by substitution with functional (e.g., charged) groups or other covalent attachments. The general structure of the neutral soluble glucan is shown in FIG. 1. The biologically active preparation of this invention is a conformationally purified form of β-glucan produced by dissociating the native glucan conformations and re-annealing and purifying the resulting unique triple helical conformation. The unique conformation of the neutral soluble glucan contributes to the glucan's ability to selectively activate the immune system without stimulating the production of detrimental biochemical mediators.
  • [0022]
    The neutral soluble glucan preparations of this invention are prepared from insoluble glucan particles, preferably derived from yeast organisms. See Manners et al., Biochem. J., 135:19-30, (1973) for a general procedure to make insoluble yeast glucans. Glucan particles which are particularly useful as starting materials in the present invention are whole glucan particles (WGP) described by Jamas et al., in U.S. Pat. Nos. 4,810,646, 4,992,540, 5,082,936 and 5,028,703, the teachings of all of which are hereby incorporated herein by reference. The source of the whole glucan particles can be the broad spectrum of glucan-containing yeast organisms which contain β-glucans in their cell walls. Whole glucan particles obtained from the strains Saccharomyces cerevisiae R4 (NRRL Y-15903; deposit made in connection with U.S. Pat. No. 4,810,646) and R4 Ad (ATCC No. 74181) are particularly useful. Other strains of yeast that can be used include Saccharomyces delbrueckii, Saccharomyces rosei, Saccharomyces microellinsodes, Saccharomyces carlsbercensis, Schizosacharomyces pombe, Kluyveromycies lactis, Kluyveromyces fragilis, Kluyveromyces polysporus, Candida albicans, Candida cloacae, Candida troipicalis, Candida utilis, Hansenula wingeri, Hansenula arni, Hansenula henricii, Hansenula americana.
  • [0023]
    A procedure for extraction of whole glucan particles is described by Jamas et al., in U.S. Pat. Nos. 4,810,646, 4,992,540, 5,082,936 and 5,028,703. For the purpose of this present invention, it is not necessary to conduct the final organic extraction and wash steps described by Jamas et al.
  • [0024]
    In the present process, whole glucan particles are suspended in an acid solution under conditions sufficient to dissolve the acid-soluble glucan portion. For most glucans, an acid solution having a pH of from about 1 to about 5 and at a temperature of from about 20 to about 100° C. is sufficient. Preferably, the acid used is an organic acid capable of dissolving the acid-soluble glucan portion. Acetic acid, at concentrations of from about 0.1 to about 5 M or formic acid at concentrations of from about 50% to 98% (w/v) are useful for this purpose. The treatment time may vary from about 10 minutes to about 20 hours depending on the acid concentration, temperature and source of whole glucan particles. For example, modified glucans having more (1-6) branching than naturally-occurring, or wild-type glucans, require more stringent conditions, i.e., longer exposure times and higher temperatures. This acid-treatment step can be repeated under similar or variable conditions. One preferred processing method is described in the exemplification using glucan derived from S. cerevisiae strain R4 Ad. In another embodiment of the present method, whole glucan particles from the strain, S. cerevisiae R4, which have a higher level of β(1-6) branching than naturally-occurring glucans, are used, and treatment is carried out with 90% (w/v) formic acid at 20° C. for about 20 minutes and then at 85° C. for about 30 minutes.
  • [0025]
    The insoluble glucan particles are then separated from the solution by an appropriate separation technique, for example, by centrifugation or filtration. The pH of the resulting slurry is adjusted with an alkaline compound such as sodium hydroxide, to a pH of about 7 to about 14. The precipitate is collected by centrifugation and is boiled in purified water (e.g., USP) for three hours. The slurry is then resuspended in hot alkali having a concentration sufficient to solubilize the glucan polymers. Alkaline compounds which can be used in this step include alkali-metal or alkali-earth metal hydroxides, such as sodium hydroxide or potassium hydroxide, having a concentration of from about 0.01 to about 10 N. This step can be conducted at a temperature of from about 40° C. to about 121° C., preferably from about 20° C. to about 100° C. In one embodiment of the process, the conditions utilized are a 1 M solution of sodium hydroxide at a temperature of about 80-100° C. and a contact time of approximately 1-2 hours. The resulting mixture contains solubilized glucan molecules and particulate glucan residue and generally has a dark brown color due to oxidation of contaminating proteins and sugars. The particulate residue is removed from the mixture by an appropriate separation technique, e.g., centrifugation and/or filtration. In another embodiment of the process the acid-soluble glucans are precipitated after the preceding acid hydrolysis reaction by the addition of about 1.5 volumes of ethanol. The mixture is chilled to about 4° C. for two (2) hours and the resulting precipitate is collected by centrifugation or filtration and washed with water. The pellet is then resuspended in water, and stirred for three (3) to twelve (12) hours at a temperature between about 20° C. and 100° C. At this point the pH is adjusted to approximately 10 to 13 with a base such as sodium hydroxide.
  • [0026]
    The resulting solution contains dissociated soluble glucan molecules. This solution is now purified to remove traces of insoluble glucan and high molecular weight soluble glucans which can cause aggregation. This step can be carried out by an appropriate purification technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight (NMW) levels or cut-offs in the range of about 1,000 to 100,000 daltons. It was discovered that in order to prevent gradual aggregation or precipitation of the glucan polymers the preferred membrane for this step has a nominal molecular weight cut-off of about 100,000 daltons. The soluble glucan is then further purified at alkaline pH to remove low molecular weight materials. This step can be carried out by an appropriate purification technique, for example, by ultrafiltration, utilizing membranes with nominal molecular weight levels or cut-offs in the range of 1,000 to 30,000 daltons.
  • [0027]
    The resulting dissociated soluble glucan is re-annealed under controlled conditions of time (e.g., from about 10 to about 120 minutes), temperature (e.g., from about 50 to about 70° C.) and pH. The pH of the solution is adjusted to the range of about 3.5-11 (preferably 6-8) with an acid, such as hydrochloric acid. The purpose of this re-annealing step is to cause the soluble glucan to rearrange from a single helix conformation to a new ordered triple helical conformation. The re-annealed glucan solution is then size fractionated, for example by using 30,000-70,000 NMW and 100,000-500,000 NMW cut-off membrane ultrafilters to selectively remove high and low molecular weight soluble glucans. Prior to sizing, the soluble glucans exist as a mixture of conformations including random coils, gel matrices or aggregates, triple helices and single helices. The objective of the sizing step is to obtain an enriched fraction for the re-annealed conformation of specific molecular weight. The order in which the ultrafilters are used is a matter of preference.
  • [0028]
    The concentrated fraction obtained is enriched in the soluble, biologically active neutral soluble glucan. The glucan concentrate is further purified, for example, by diafiltration using a 10,000 dalton membrane. The preferred concentration of the soluble glucan after this step is from about 2 to about 10 mg/ml.
  • [0029]
    The neutralized solution can then be further purified, for example, by diafiltration, using a pharmaceutically acceptable medium (e.g., sterile water for injection, phosphate-buffered saline (PBS) , isotonic saline, dextrose) suitable for parenteral administration. The preferred membrane for this diafiltration step has a nominal molecular weight cut-off of about 10,000 daltons. The final concentration of the glucan solution is adjusted in the range of about 0. 5 to 10 mg/ml. In accordance with pharmaceutical manufacturing standards for parenteral products, the solution can be terminally sterilized by filtration through a 0.22 μm filter. The neutral soluble glucan preparation obtained by this process is sterile, non-antigenic, essentially pyrogen-free, and can be stored at room temperature (e.g., 15-30° C.) for extended periods of time without degradation. This process is unique in that it results in a neutral aqueous solution of (pH 4.5 to 7.0) immunologically active glucans which is suitable for parenteral administration.
  • [0030]
    For purposes of the present invention, the term “soluble” as used herein to describe glucans obtained by the present process, means a visually clear solution can be formed in an aqueous medium such as water, PPBS, isotonic saline, or a dextrose solution having a neutral pH (e.g., from about pH 5 to about 7.5), at room temperature (about 20-25° C.) and at a concentration of up to about 10 mg/ml. The term “aqueous medium” refers to water and water-rich phases, particularly to pharmaceutically acceptable aqueous liquids, including PBS, saline and dextrose solutions. The expression “visually clear” means that at a concentration of a mg/ml, the absorption of the solution at 530 nm is less than OD 0.01 greater than the OD of an otherwise identical solution lacking the B-glucan component.
  • [0031]
    The resulting solution is substantially free of protein contamination, is non-antigenic, non-pyrogenic and is pharmaceutically acceptable for parenteral administration to animals and humans. However, if desired, the soluble glucan can be dried by an appropriate drying method, such as lyophilization, and stored in dry form.
  • [0032]
    The neutral soluble glucans of this invention can be used as safe, effective, therapeutic and/or prophylactic agents, either alone or as adjuvants, to enhance the immune response in humans and animals. Soluble glucans produced by the present method selectively activate only those components that are responsible for the initial response to infection, without stimulating or priming the immune system to release certain biochemical mediators (e.g., IL-1, TNF, IL-6, IL-8 and GM-CSF) that can cause adverse side effects. As such, the present soluble glucan composition can be used to prevent or treat infectious diseases, in malnourished patients, patients undergoing surgery and bone marrow transplants, patients undergoing chemotherapy or radiotherapy, neutropenic patients, HIV-infected patients, trauma patients, burn patients, patients with chronic or resistant infections such as those resulting from myeiodysplastic syndrome, and the elderly, all of who may have weakened immune systems. An immunocompromised individual is generally defined as a person who exhibits an attenuated or reduced ability to mount, a normal cellular and/or humoral defense to challenge by infectious agents, e.g., viruses, bacteria, fungi and protozoa. A protein malnourished individual is generally defined as a person who has a serum albumin level of less than about 3.2 grams per deciliter (g/dl) and/or unintentional weight loss of greater than 10% of usual body weight.
  • [0033]
    More particularly, the method of the invention can be used to therapeutically or prophylactically treat animals or humans who are at a heightened risk of infection due to imminent surgery, injury, illness, radiation or chemotherapy, or other condition which deleteriously affects the immune system. The method is useful to treat patients who have a disease or disorder which causes the normal metabolic immune response to be reduced or depressed, such as HIV infection (AIDS). For example, the method can be used to pre-initiate the metabolic immune response in patients who are undergoing chemotherapy or radiation therapy, or who are at a heightened risk for developing secondary infections or post-operative complications because of a disease, disorder or treatment resulting in a reduced ability to mobilize the body's normal metabolic responses to infection. Treatment with the neutral soluble glucans has been shown to be particularly effective in mobilizing the host's normal immune defenses, thereby engendering a measure of protection from infection in the treated host.
  • [0034]
    The present-composition is generally administered to an animal or a human in an amount sufficient to produce immune system enhancement. The mode of administration of the neutral soluble glucan can be oral, enteral, parenteral, intravenous, subcutaneous, intraperitoneal, intramuscular, topical or intranasal. The form in which the composition will be administered (e.g., powder, tablet, capsule, solution, emulsion) will depend upon the route by which it is administered. The quantity of the composition to be administered will be determined on an individual basis, and will be based at least in part on consideration of the severity of infection or injury in the patient, the patient's condition or overall health, the patient's weight and the time available before surgery, chemotherapy or other high-risk treatment. In general, a single dose will preferably contain approximately 0.01 to approximately 10 mg of modified glucan per kilogram of body weight, and preferably from about 0.1 to 2.5 mg/kg. The dosage for topical application will depend upon the particular wound to be treated, the degree of infection and severity of the wound. A typical dosage for wounds will be from about 0.001 mg/ml to about 2 mg/ml, and preferably from about 0.01 to about 0.5 mg/ml.
  • [0035]
    In general, the compositions of the present invention can be administered to an individual periodically as necessary to stimulate the individual's immune response. An individual skilled in the medical arts will be able to determine the length of time during which the composition is administered and the dosage, depending upon the physical condition of the patient and the disease or disorder being treated. As stated above, the composition may also be used as a preventative treatment to preinitiate the normal metabolic defenses which the body mobilizes against infections.
  • [0036]
    Neutral soluble β-glucan can be used for the prevention and treatment of infections caused by a broad spectrum of bacterial, fungal, viral and protozoan pathogens. The prophylactic administration of neutral soluble β-glucan to a person undergoing surgery, either preoperatively, intraoperatively and/or post-operatively, will reduce the incidence and severity of post-operative infections in both normal and high-risk patients. For example, in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated (e.g., gastrointestinal surgery, hysterectomy, cesarean section, transurethral prostatectomy) and in patients in whom infection at the operative site would present a serious risk (e.g., prosthetic arthroplasty, cardiovascular surgery), concurrent initial therapy with an appropriate antibacterial agent and the present neutral soluble glucan preparation will reduce the incidence and severity of infectious complications.
  • [0037]
    In patients who are immunosappressed, not only by disease (e.g., cancer, AIDS) but by courses of chemotherapy and/or radiotherapy, the prophylactic administration of the soluble glucan will reduce the incidence of infections caused by a broad spectrum of opportunistic pathogens including many unusual bacteria, fungi and viruses. Therapy using neutral soluble β-glucan has demonstrated a significant radio-protective effect with its ability to enhance and prolong macrophage function and regeneration and, as a result enhance resistance to microbial invasion and infection.
  • [0038]
    In high risk patients (e.g., over age 65, diabetics, patients having cancer, malnutrition, renal disease, emphysema, dehydration, restricted mobility, etc.) hospitalization frequently is associated with a high incidence of serious nosocomial infection. Treatment with neutral soluble β-glucan may be started empirically before catheterization, use of respirators, drainage tubes, intensive care units, prolonged hospitalizations, etc. to help prevent the infections that are commonly associated with these procedures. Concurrent therapy with antimicrobial agents and the neutral soluble β-glucan is indicated for the treatment of chronic, severe, refractory, complex and difficult to treat infections.
  • [0039]
    The compositions administered in the method of the present invention can optionally include other components, in addition to the neutral soluble β-glucan. The other components that can be included in a particular composition are determined primarily by the manner in which the composition is to be administered. For example, a composition to be administered orally in tablet form can include, in addition to neutral soluble β-glucan, a filler (e.g., lactose), a binder (e.g., carboxymethyl cellulose, gum arabic, gelatin), an adjuvant, a flavoring agent, a coloring agent and a coating material (e.g., wax or plasticizer). A composition to be administered in liquid form can include neutral soluble β-glucan and, optionally, an emulsifying agent, a flavoring agent and/or a coloring agent. A composition for parenteral administration can be mixed, dissolved or emulsified in water, sterile saline, PBS, dextrose or other biologically acceptable carrier. A composition for topical admihistration can be formulated into a gel, ointment, lotion, cream or other form in which the composition is capable of coating the site to be treated, e.g., wound site.
  • [0040]
    Compositions comprising neutral soluble glucan can also be administered topically to a wound site to stimulate and enhance wound healing and repair. Wounds due to ulcers, acne, viral infections, fungal infections or periodontal disease, among others, can be treated according to the methods of this invention to accelerate the healing process. Alternatively, the neutral soluble β-glucan can be infected into the wound or afflicted area. In addition to wound repair, the composition can be used to treat infection associated therewith or the causative agents that result in the wound. A composition for topical administration can be formulated into a gel, ointment, lotion, cream or other form in which the composition is capable of coating the site to be treated, e.g., wound site. The dosage for topical application will depend upon the particular wound to be treated, the degree of infection and severity of the wound. A typical dosage for wounds will be from about 0.01 mg/ml to about 2 mg/ml, and preferably from about 0.01 to about 0.5 mg/ml.
  • [0041]
    Another particular use of the compositions of this invention is for the treatment of myeiodysplastic syndrome (IDS). MDS, frequently referred to as preleukemia syndrome, is a group of clonal hematopoietic stem cell disorders characterized by abnormal bone marrow differentiation and maturation leading to peripheral cytopenia with high probability of eventual leukemic conversion. Recurrent infection, hemorrhaging and terminal infection resulting in death typically accompany MDS. Thus, in order to reduce the severity of the disease and the frequency of infection, compositions comprising modified glucan can be chronically administered to a patient diagnosed as having MDS according to the methods of this invention, in order to specifically increase the infection fighting activity of the patient's white blood calls. Other bone marrow disorders, such as a plastic anemia (a condition of quantitatively reduced and defective hematopciesis) can be treated to reduce infection and hemorrhage that are associated with this disease state.
  • [0042]
    Neutral soluble glucan produced by the present method enhances the non-specific defenses of mammalian mononuclear cells and significantly increases their ability to respond to an infectious challenge. The unique property of neutral soluble glucan macrophage activation is that it does not result in increased body temperatures (i.e. fever) as has been reported with many non-specific stimulants of those defenses. This critical advantage of neutral soluble glucan may lie in the natural profile of responses it mediates in white blood cells. It has been shown that the neutral soluble β-glucan of the present invention selectively activates immune responses but does not directly stimulate or prime cytokine (e.g., IL-1 and TNF) release from mononuclear cells, thus distinguishing the present neutral soluble glucan from other glucan preparations (e.g., lentinan, kresein) and immunostimulants.
  • [0043]
    In addition, it has been-demonstrated herein that the neutral soluble glucan preparation of the present invention possesses an unexpected platelet stimulating property. Although it was known that glucans have the ability to stimulate white blood cell hematopoiesis, the disclosed platelet stimulating property had not been reported or anticipated. This property can be exploited in a therapeutic regimen for use as an adjuvant in parallel with radiation or chemotherapy treatment. Radiation and chemotherapy are known to result in neutropenia (reduced polymorphonuclear (PMN) leukocyte cell count) and thrombocytopenia (reduced platelet count). At present, these conditions are treated by the administration of colony-stimulating factors such as GM-CSF and granulocyte colony-stimulating factor (G-CSF). Such factors are effective in overcoming neutropenia, but fail to impact upon thrombocytopenia. Thus, the platelet stimulating property of the neutral soluble glucan preparation of this invention can be used, for example, as a therapeutic agent to prevent or minimize the development of thrombocytopenia which limits the dose of the radiation or chemotherapeutic agent which is used to treat cancer.
  • [0044]
    The invention is further illustrated by the following Examples.
  • EXAMPLES Example 1: Preparation Of Neutral Soluble Glucan From S. Cerevisiae
  • [0045]
    [0045]Saccharomyces cerevisiae strain R4 Ad (a non-recombinant derivative of wild-type strain A364A), was grown in a large-scale fermentation culture using a defined glucose, ammonium sulfate minimal medium. The production culture was maintained under glucose limitation in a feed-batch-mode (New Brunswick MPP80). When the growing culture reached late logarithmic phase, the fermentation was ended and the β-glucan was stabilized by adjusting the culture to pH 12±0.5 using 10 M NaOH. The yeast cells containing β-glucan were harvested by continuous-flow centrifugation (Westfalia SA-1). After centrifugation, the cells were collected into a stainless steel extraction vessel.
  • [0046]
    The first step in the extraction process was an alkaline extraction accomplished by mixing the cells with 1 M sodium hydroxide (NaOH) at 90±5° C. for 1 hour. Upon completion of this alkaline extraction, the β-glucan remained in the solid phase, which was collected by continuous centrifugation (Westfalia SA-1). The collected cell wall fraction was extracted a second time using the same procedure and under the same conditions. Treatment with alkali hydrolyzed and solubilized the cellular proteins, nucleic acids, mannans, soluble glucans and polar lipids into the supernatant fraction, and deacety-lated chitin to chitosan in the cell wall.
  • [0047]
    The second step in the extraction process was a pH 4.5±10.05 (adjusted with concentrated HCl) extraction at 75±0.5° C. for 1 hour. This was followed by a 0.1 M acetic acid extraction to complete the removal of glycogen, chitin, chitosan and remaining proteins. The solids were collected and rinsed twice with Purified Water USP to remove any residual acid as well as any yeast degradation products.
  • [0048]
    The third step in the extraction process was a set of six organic extractions. The first four extractions were carried out in isopropanol. The solids were collected by centrifugation and then subjected to two acetone extractions. The two-stage organic extractions eliminated nonpolar lipids and hydrophobic proteins which may have co-purified with the drug substance. The resulting wet solids were dried in a vacuum oven at 65±5° C. for 48-96 hours to yield a free-flowing powder.
  • [0049]
    At this stage the extraction process yielded a stable, insoluble intermediate consisting of approximately 90% β-glucan, called whole glucan particles (WGPs). The dry WGP intermediate was stored at 15-30° C. until further use.
  • [0050]
    The WGP powder was resuspended in 98% (w/v) formic acid, in a glass reaction vessel at room temperature. The resulting mixture was heated to 85±5° C. for 20 minutes. Under these conditions, the WGPs were partially hydrolyzed and solubilized to provide the desired molecular weight distribution of soluble β-glucan which was then precipitated by adding 1.5 volumes of ethanol. After complete mixing, the preparation was centrifuged to collect the β-glucan precipitate. Any residual formic acid was removed by boiling the β-glucan preparation in Purified Water USP for three hours.
  • [0051]
    Any unhydrolyzed WGPs were then removed from the β-glucan solution by centrifugation. The β-glucan solution was raised to pH 12.5±0.5 by the addition of the concentrated sodium hydroxide. The remaining purification steps were carried out by ultrafiltration.
  • [0052]
    The soluble alkaline β-glucan preparation was passed through a 100,000 nominal molecular weight (NMW) cut-off membrane ultrafilter (Amicon DC10). Under alkaline conditions this membrane ultrafilter removed insoluble and high. molecular weight soluble β-glucan. Trace low molecular weight degradation products were then removed by recirculation through a 10,000 NMW cut-off membrane ultrafilter. The ultrafiltration was conducted as a constant volume wash with 0.1 M NaOH.
  • [0053]
    The β-glucan solution was re-annealed under controlled conditions by adjusting the pH to 7.0±0.5 with concentrated hydrochloric acid, heating to 60±10° C., which was maintained for 20 minutes and then cooled. The neutral re-annealed solution was then concentrated and washed with Sodium Chloride Injection USP in a 70,000 NMW cut-off membrane ultrafilter (Filtron Minisep) to enrich for the re-annealed neutral soluble glucan. Next the material was filtered through a 300,000 NMW cut-off membrane ultrafilter (Filtron Minisep) to remove high molecular weight and aggregated glucan molecules. In the same ultrrafilter, the neutral soluble glucan material was washed with Sodium Chloride Injection USP in a constant volume wash mode.
  • [0054]
    The neutral soluble glucan was then concentrated in a 10,000 NMW cut-off membrane ultrafilter. The concentration process continued until a concentration of at least 1.0 mg/ml hexose equivalent was achieved.
  • [0055]
    The resulting neutral soluble glucan was then subjected to filtration through a depyrogenating filter (0.1 micron Posidyne) and a sterile 0.2 micron filter (Millipak) to yield sterile, pyrogen-free neutral soluble glucan. The neutral soluble glucan solution was stored at controlled room temperature (15-30° C.) until further use. The aqueous solubility of neutral soluble glucan in the pH range of 4 to 8 is approximately 100 mg/ml. The solubility increased with increasing pH and reached approx. 150 mg/ml at pH 13.
  • Example 2: Analysis Of Neutral Soluble Glucan
  • [0056]
    A. Glucose, Mannose and Glucosanine
  • [0057]
    Monosaccharide analysis was performed to quantitate the relative amounts of β-glucan (as glucose), mannan or phosphomannan (as mannose), and chitin (as N-acetyl glucosamine) in the neutral soluble glucan. The sample was hydrolyzed to monosaccharides in 2 M trifluoroacetic acid for 4 hours at 110° C., evaporated to dryness, and redissolved in water. Monosaccharides were separated on a Dionex HPLC system using a CarboPac PA100 column (4×250 mm) using 5 M NaOH at 1 ml/min and quantitated using a pulsed electrochemical detector (Dionex Model PED-1). The sensitivity of this assay for monosaccharides is 0.1% (w/w).
  • [0058]
    Glucose (retention time of 16.6 mm) was identified as the only monosaccharide component of neutral soluble glucan along with traces of glucose degradation products (from hydrolysis) anhydroglucose at 2.5 min and 5-hydroxymethylfurfural at 4.3 min. The results confirm that neutral soluble glucan consisted of ≧98% glucose.
  • [0059]
    B. FTIR
  • [0060]
    Fourier transform infrared spectroscopy by diffuse reflectance (FTIR, Matson Instruments, Polaris) of lyophilized neutral soluble glucan samples was used to determine the anomeric structure (α vs. β), and linkage type (β(1-3), β(1-6), β(1-4)) present in neutral soluble glucan. Absorption maxima of 890 cm−1 identified β(1-3) linkages; 920 cm−1 identified β(1-6) linkages. No presence of α-linked anomers (e.g., glycogen, 850 cm−1) or β(1-4)-linked polysaccharides (e.g., chitin, 930 cm−1) were detected.
  • Example 3: Conformational Analysis
  • [0061]
    A solution of β-glucan which was not processed by alkali dissociation and re-annealing was analyzed for its compositional identity by gel permeation chromatography (pH 7) and found to contain multiple species, referred to herein as high molecular weight aggregate (Ag), Peak A and Peak B (See FIG. 2). Neutral soluble glucan which was prepared by alkali dissociation and re-annealing as described in Example 1, is present as a single peak (see FIG. 3) with an average molecular weight of 92,660 daltons at pH 7. The distinct conformations of neutral soluble glucan and Peak B were demonstrated by gel permeation chromatography at pH 7 and pH 13 using a refractive index detector. Neutral soluble glucan underwent a significant conformational transition from pH 7 to pH 13 which illustrates complete dissociation of the multiple helix at pH 7 to a single helical form at pH 13 (see FIG. 3). In contrast, Peak B only underwent a slight shift in molecular weight from pH 7 to pH 13 (see FIG. 4). The molecular weight of neutral soluble glucan and Peak B glucans as a function of pH is shown below in Table 1.
    TABLE 1
    MW MW Ratio
    Sample pH 7 pH 13 (pH 7/pH 13)
    Neutral soluble 92,666 18,693 4.96
    glucan
    Peak B 8,317 7,168 1.16
  • [0062]
    The conformation of neutral soluble glucan and Peak B glucan was also determined by aniline blue complexing (Evans et al., 1984, Carb. Pol., 4:215-230; Adachi et al., 1988, Carb. Res., 177: 91-100), using curdlan, a linear β(1-3) glucan, as the triple helix control and pustulan, a β(1-6) glucan, as a non-ordered conformational control. The results are discussed below and shown in Table 2.
  • [0063]
    The curdlan triple helix control complexed with aniline blue resulting in high fluorescence. Increasing the NaOH concentration began to dissociate the curdlan triple helix slightly, but NaOH concentrations >0.25 M are required for complete dissociation of curdlan. The pustulan non-ordered control only formed a weak complex with aniline blue resulting in low fluorescence measurements which were not affected by NaOH concentration.
  • [0064]
    The neutral soluble glucan complexed effectively with aniline blue at low NaOH concentration (25 mM NaOH) resulting in high fluorescence. However, the neutral soluble glucan conformation dissociated significantly (50%) at NaOH concentrations as low as 150 mM NaOH indicating that it exists as a unique conformation compared to naturally occurring β-glucans, such as laminarin and curdlan, which require significantly higher NaOH concentrations for dissociation to occur. Peak B formed a weak complex with aniline blue due to its single helical conformation.
    TABLE 2
    Conformational Analysis of Glucans
    by Aniline Blue Complexing
    Fluorescence
    25 mM 100 mM 150 mM
    Test Material NaOH NaOH NaOH
    Blank 0 2 0
    Curdlan 53.5 41.6 36
    β(1-3) glucan
    Pustulan 9.8 8.3 8.0
    β(1-6) glucan
    Neutral soluble glucan 40 25.6 20.2
    Peak B 12.4 6.2 4.1
  • Example 4: Effects Of Neutral Soluble Glucan On Human Monocyte Production Of TNFα
  • [0065]
    Human peripheral blood mononuclear cells were isolated (Janusz et al., (1987), J. Immunol., 138: 3897-3901) from normal citrated and dextran-treated blood, washed in Hank's balanced salt solution (HBSS), lacking calcium, magnesium, and phenol red, and purified by gradient centrifugation on cushions of Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, N.J.). The mononuclear cells were collected into HBSS, washed twice, resuspended in RPMI 1640 Medium (Gibco, Grand Island, N.Y.) containing 1% heat-inactivated autologous serum (56° C. for 30 min.), and counted on the Coulter counter.
  • [0066]
    For the preparation of monocyte monolayers, 1 ml of 2.2×106 mononuclear cells/ml was plated into wells of 24-well tissue culture plates (Costar, Cambridge, Mass.), incubated for 1 hour at 37° C. in a humidified atmosphere of 5% CO2, and washed three times with RPMI to remove nonadherent cells. A second 1 ml aliquot of 2.2×106 mononuclear cells/ml was layered into each well and incubated for 2 hours described above before removal of the nonadherent cells. By visual enumeration at 40X with an inverted phase microscope and a calibrated reticle, the number of adherent calls for 30 different donors was 0.77±0.20×106 per well (mean±SD). By morphology and nonspecific esterase staining, >95% of the adherent cells were monocytes.
  • [0067]
    Monocyte monolayers were incubated at 37° C. in the CO2 chamber for 0 to 8 hours with 0.5 ml of RPMI, 1% heat-inactivated autologous serum, 10 mM EPES, and 5 mM MgCl2 in the absence and presence of various glucan preparations. The culture supernatant was removed, clarified by centrifugation at 14,000 g for 5 min at 4° C., and stored at −70° C. before assay of TNFα.
  • [0068]
    The concentration of TNFα in the monocyte supernatants was measured by an enzyme-linked immunoadsorbent assay (ELISA) with the BIORINE TNF Test kit (T Cell Sciences, Cambridge, Mass.), which had a lower limit of detectability of 40 pg/ml. The data are expressed as pg per 106 monocytes, which was calculated by dividing the quantity of cytokine in 0.5 ml of supernatant by the number of monocytes per well.
  • [0069]
    For the determination of cell-associated levels of TNFα, the adherent monocytes were lysed in 0.25 ml PBS by three rounds of freezing and thawing, the lysates were cleared of debris by centrifugation at 14,000 g for 5 min at 4° C., and the resulting supernatants were stored at −70° C. Newly prepared monocyte monolayers contained no detectable levels of intracellular TNFα.
  • [0070]
    The results are shown in Tables 3 and 4 below.
    TABLE 3
    TNFα Synthesis by Human Monocytes Stimulated
    with Various Glucan Preparations
    TNFα (pg/106 monocytes)
    Glucan Conc. 1 2 3 Mean ± SD
    Buffer Control 36 39 2 26 ± 21
    Neutral soluble 1 mg/ml 44 51 33 43 ± 9
    glucan
    Laminarin 1 mg/ml 372 324 227 308 ± 74
    Whole 4 × 107/ml 2129 1478 1683 1763 ± 333
    Glucan particles
  • [0071]
    [0071]
    TABLE 4
    TNFα Stimulation by Different Conformational
    Structures of Soluble β-Glucan
    TNFα
    Glucan Conc. (pg/106 monocytes)
    Buffer Control 1 mg/ml 40
    Laminarin 1 mg/ml 1312
    Neutral soluble glucan 1 mg/ml 16
    Peak B 1 mg/ml 1341
    Glucan Particles 4 ± 107/ml 2065
  • [0072]
    Table 3 shows that TNFα was stimulated by insoluble glucan particles and by laminarin, a soluble β(1-6) and β(1-3) linked glucan. There was no stimulation of TNFα by neutral soluble glucan. Table 4 shows similar results, but further confirms that TNFα stimulation is dependent upon conformational structure. The neutral soluble glucan did not stimulate TNFα while Peak B (single helical conformation) did stimulate TNFα.
  • Example 5: Avidity Of Neutral Soluble Glucan For The Glucan Receptor
  • [0073]
    Monolayers of human monocytes, prepared on siliconized glass coverslips (Czop et al., 1978, J. Immunol., 120:1132), were incubated for 18 minutes at 37° C. in a humidified 5% CO2 incubator with either 0.25 ml of buffer (RPMI-Mg-HEPES) or a range of concentrations (0.1-50 μg/ml) of neutral soluble glucan. The monocyte monolayers were then washed twice with 50 ml of RPMI 1640 medium and were layered with 0.25 ml of 4.8×106/ml zymosan particles (Czop and Austen, 1985, J. Immunol., 134:2588-2593). After a 30 minute incubation at 37° C., the monolayers were washed three times with 50 ml of Hank's balanced salt solution to remove noningested zymosan particles. The monolayers were then fixed and stained with Giemsa. The ingestion of zymosan particles by at least 300 monocytes per monolayer was determined by visual observation under a 1000X light microscope.
  • [0074]
    Monocyte monolayers protreated with buffer, 50 or 500 μg/ml of neutral soluble glucan as described above were subsequently tested for their capacity to ingest IgG coated sheep erythrocytes (E′IgG). After an 18 minute preincubation with the neutral soluble glucan, the monolayers were incubated with 0.25 ml of 1×107/ml E′IgG for 30 minutes at 37° C., washed three times with 50 ml of Hank's balanced salt solution, treated for 4 minutes with 0.84% NH4Cl to lyse noningested E′IgG, and fixed and stained as described above. The percentages of monocytes ingesting ≧1 and ≧3 E′IgG were determined by counting at least 300 monocytes per monolayer.
  • [0075]
    The percent inhibition of monocyte ingestion was determined by subtracting the percentage of monocytes ingesting targets after pretreatment with the neutral soluble glucan from the percentage ingesting targets after pretreatment with buffer, dividing this number by the percentage ingesting targets after pretreatment with buffer and multiplying by 100. The data are expressed as the mean of two experiments and are reported in Table 5.
    TABLE 5
    Glucan-receptor Binding Capacity of
    Distinct Conformations of Soluble β-glucans
    Test Material Conc. % Inhibition
    Buffer  0%
    Neutral soluble glucan  50 μg/ml 74%
    500 μg/ml 86%
    Peak B  50 μg/ml 50%
    500 μg/ml 56%
  • [0076]
    Both β-glucan preparations tested above inhibited monocyte ingestion of zymosan particles demonstrating their capacity to competitively bind to the β-glucan receptor, on human monocytes. Neutral soluble glucan demonstrated a higher receptor binding capacity than Peak B as indicated by the greater level of inhibition achieved at both 50 μg/ml and 500 μg/ml. This biological assay demonstrates that the neutral soluble glucan is a superior ligand for the β-glucan receptor.
  • Example 6: Lack Of In Vitro Stimulation Of IL-1βAnd TNFα From Human Mononuclear Cells
  • [0077]
    Venous blood was obtained from healthy male volunteers and mononuclear cells were fractionated by Ficoll-Hypacue centrifugation. The mononuclear cells were washed, resuspended in endotoxin-free RPMI-1640 culture medium—ultrafiltered to remove endotoxins as described elsewhere (Dinarello et al., 1987, J. Clin. Microbiol. 25:1233-8)—at a concentration of 5×106 cells/ml and were aliquoted into 96-well microtiter plates (Endres et al., 1989, N. E. J. Med. 320:265-271). The cells were then incubated with either 1 ng/ml endotoxin (lipopolysaccharide, E. coli 055:B5, Sigma, St. Louis), or 10 to 1000 ng/ml βglucan, at 37° C. for 24 hours in 5% CO2 and then lysed by three freeze-thaw cycles (Endres et al., 1989, N. E. J. Med. 320:265-271). Synthesis of IL-1β, and TNFα was determined by specific radioimmunoassays as described elsewhere (List et al., 1987, Lymph Res. 6:229-244; Lonnemann et al., 1988, Lymph. Res. 7:75-84; Van der Meer et al., 1988, J. Leukocyte Biol. 43:216-223.
  • [0078]
    To determine if neutral soluble glucan could act endotoxin, a known cytokine stimulant, mononuclear cells were pre-incubated- with 1, 10, and 1000 ng/ml of the neutral soluble glucan for 3 hours at 37° C. in 5% CO2. The cells were washed to remove neutral soluble glucan and were then incubated with 1 ng/ml endotoxin as described above. IL-1β and TNFα were determined as described above.
  • [0079]
    The results are summarized in Table 6. Neutral soluble glucan used as a stimulant at doses of 10-1000 ng/ml alone did not induce increased levels of IL-1β or TNFα synthesis over the control buffer treated cells. Endotoxin LPS, a known stimulant, resulted in significantly increased levels of both cytokines. In a second phase of this experiment neutral soluble glucan was tested for its ability to act as a priming agent for mononuclear cell cytokine synthesis. The cells from the same donors were pre-incubated with three doses of neutral soluble glucan (10-1000 ng/ml) and were then exposed to endotoxin as a co-stimulant. Neutral soluble glucan did not result in any amplification of the IL-1β and TNFα levels compared to endotoxin alone.
    TABLE 6
    In Vitro IL-1β and TNFα Synthesis by
    Human Peripheral Blood Mononuclear Cells
    IL-1β TNFα
    Stimulant (ng/ml)1 (ng/ml)1
    Cells only <0.10 0.14
    Neutral  10 ng/ml 0.13 0.16
    soluble  100 ng/ml 0.12 0.16
    glucan 1000 ng/ml <0.10 0.14
    LPS   1 ng/ml 2.62 2.22
    LPS (1 ng/ml) +  10 ng/ml 2.62 2.25
    Neutral  100 ng/ml 2.57 2.07
    soluble 1000 ng/ml 2.85 2.27
    glucan
  • Example 7: In Vivo Protection Against Infection In Mice
  • [0080]
    A sepsis model was developed in rats to characterize the efficacy of β-glucan in protecting an immunologically intact host against serious infections, such as those which commonly occur following abdominal.. surgery. The rat model for intra-abdominal sepsis has been well described in the scientific literature (Onderdonk et al., 1974, Infect. Imun., 10:1256-1259).
  • [0081]
    Groups of rats received neutral soluble glucan (100 μg/0.2 ml) or saline control (0.2 ml) intramuscularly 24 hours and 4 hours prior to infectious challenge. A defined polymicrobic infectious challenge (cecal inoculum) was placed into a gelatin capsule which was then surgically implanted into the peritoneal cavity of anesthetized rats through an anterior midline incision. The early peritonitis from this experimentally induced infection was associated with the presence of gram-negative organisms within the blood and peritoneal cavity culminating in mortality. The cecal inoculum contained an array of facultative species, such E. coli, as well as other obligate anaerobes (Streptococcus sp., Bacteroides sp., Clostridium perfringens, Clostridium ramosum, Peptostretococus racrus and broductus, Proteus mirabilis). The animals were observed four times per day for the first 48 h and twice per day thereafter. The results are reported in Table 7.
    TABLE 7
    Effect of Neutral Soluble Glucan on Mortality in a Rat
    Model for Intra-abdominal Sepsis
    Group Mortality (%) P vs. Saline
    Saline 12/20 (60)
    Neutral soluble glucan  2/10 (10) <0.01
  • [0082]
    These results demonstrate that neutral soluble glucan which does not induce IL-1β and TNFα protects mice from lethal bacterial challenge.
  • Example 8: Demonstration Of Safety For Human Administration
  • [0083]
    A randomized, double-blind, placebo-controlled clinical trial was conducted on healthy males to evaluate the safety of neutral soluble glucan (2.25 mg/kg) injected by intravenous infusion compared to a placebo control. No adverse effects were observed. There was also no observed elevation in IL-1, TNF, IL-6, IL-8 and GM-CSF. Single intravenous administration of neutral soluble glucan resulted in an increase in monocytes and neutrophils and in the killing activity of these cells proving that neutral soluble glucan retains the desirable immunological activities in humans. See Tables 8, 9-and 10 below. However, as shown in FIGS. 5 and 6 no changes occurred in serum IL-1 and TNF and none of the patients experienced fever or inflammatory reactions. The results are consistent with the in vitro data reported in the earlier examples.
    TABLE 8
    Change In Absolute Neutrophil Counts (× 1000/μl)
    After Neutral Soluble Glucan Administration
    Dose Level B Hour 8 Hour 12 Hour 24
    Saline Mean 4.06 4.34 4.31 3.43
    SD 2.12 1.53 1.16 1.46
    N 6 6 6 6
    2.5 mg/kg Mean 4.11 11.29* 8.18 5.32
    Neutral SD 1.15 4.39 3.80 1.75
    Soluble N 6 6 6 6
    Glucan
  • [0084]
    [0084]
    TABLE 9
    Change in Monocyte Counts (× 1000/μl)
    After Soluble Neutral Glucan Administration
    Dose Level B Hour 8 Hour 12 Hour 24
    Saline Mean 0.33 0.44 0.59 0.33
    SD 0.09 0.10 0.22 0.12
    N 6 6 6 6
    2.5 mg/kg Mean 0.24 0.63* 0.67* 0.31
    Neutral SD 0.10 0.24 0.32 0.15
    Soluble N 6 6 6 6
    Glucan
  • [0085]
    [0085]
    TABLE 10
    Ex Vivo Microbicidal Activity of Normal Volunteers
    Receiving Neutral Soluble Glucan
    Mean Change in % Killing1
    Dose Level Hour 3 Hour 6 Hour 24 Day 2 Day 3 Day 6
    Saline 0 0 0 0 0 0
    2.5 mg/kg Mean 42.86 32.33 20.90 48.96 39.22 31.17
    Neutral N 6 6 6 6 6 6
    Soluble p-Value 0.062 0.036 0.300 0.045 0.085 0.026
    Glucan
  • Example 9: Demonstration Of Efficacy In Vivo As Human Anti-Invective
  • [0086]
    In this clinical study, the safety, tolerance, and potential efficacy of the neutral soluble β-glucan was evaluated in patients undergoing major thoracoabdominal surgery with high risk of post-operative infection. Thirty-four males and females who underwent surgery received 0.5 mg/kg of the neutral soluble β-glucan . preparation or saline placebo, given as an intravenous infusion of 50 to 200 ml over one hour. Patients received multiple sequential doses of the neutral soluble β-glucan or placebo at 12 to 24 hours prior to surgery, 1 to 4 hours prior to surgery, 48 hours post-surgery, and 96 hours post-surgery.
  • [0087]
    Hospitalization, infections, and usage of anti-infective medications were examined as potential clinical efficacy parameters. Compared to patients given saline placebo infusions, patients who received the neutral soluble β-glucan spent an average of five fewer days in the hospital (12.3±6.1 days versus 17.3±15.5 days) and three fewer days in the Intensive Care Unit (0.1±0.4 versus 3.3±6.3 days; p<0.03, one-way analysis of variance).
  • [0088]
    The number of anti-infective medication prescriptions written per study day following surgery was consistently higher for control patients than for β-glucan recipient patients. Control patients were prescribed an average of three times the number of anti-infective medications as β-glucan recipients over the time period from surgery to discharge (p<0.005). During the Treatment and Post-Treatment Follow-up Phases, a total of 22 culture-confirmed infections in 5 control patients and 8 infections in 5 β-glucan recipient patients were identified (p<0.002).
  • [0089]
    Neutrophils (PMNs) and monocytes/macrophages (MOs) were purified from blood samples obtained at Baseline, Day 1, and Day 5 and examined for basal and phorbol myrisate acetate stimulated microbicidal activity against Staphylococcus aureus, Escherichia coli and Candida albicans. The neutral soluble β-glucan treatment generally increased the basal and phorbol-induced microbicidal activity of MOs and PENs.
  • Example 10: Wound Healing Effects Of Neutral Soluble Glucans
  • [0090]
    Wound healing studies were performed in a hairless mouse model having full thickness wounds with and without Staphylococcus aureus infection. Hairless SKH-1 inbred mice (6-8 weeks of age) were anesthetized with ether and a midline 3 cm full thickness longitudinal incision was made with a number 10 scalpel blade, producing a full thickness wound that did not penetrate the underlying fascia. Incisions were closed using steel clips placed at 1 cm intervals.
  • [0091]
    Formulations of neutral soluble glucan in phosphate buffered saline were applied 30 minutes following wounding and reapplied at 24 hour intervals during the seven day post-operative period. Two micrograms of neutral soluble glucan/mouse per day was topically applied. Wounds were examined daily and rank-ordered for effectiveness of formulation for enhancement of visual based wound healing. Wounds were scored for closure on a scale of 0-5, with 5 indicating the most healing. In one group of mice infected, the wound was treated with a culture of 107 Staphylococcus aureus 30 minutes after wounding and 2 hrs prior to treatment with the neutral soluble glucan formulation.
  • [0092]
    Histological evaluation of the wound site of each test group was made. The dermis of the control group (untreated wound) was heavily infiltrated with both lymphocytes and monocytes/macrophages. However, re-epithelialization that occurred at the epidermal layer was incomplete. The tissue section showed that the dermal tissue was weak, in that the tissue integrity was not maintained when it was sectioned.
  • [0093]
    The histology of the wounded tissue isolated from mice treated for three days with phosphate buffered saline containing the neutral soluble glucan showed that there was a heavy infiltration of macrophages and lymphocytes. Tissue integrity was good.
  • [0094]
    When topically applied to a wound, a composition of neutral soluble glucan stimulated white blood cell entry and activity at the wound site and accelerated wound healing within the dermal layer of the wound. Furthermore, the composition effectively eliminated infection produced by bacterial infection (S. aureus) and prevented the progression to sepsis. Untreated wounds progressed to sepsis.
  • Example 11: Stimulation Of Platelet Proliferation By Neutral Soluble Glucan
  • [0095]
    The platelet proliferation stimulatory effect of the neutral soluble glucan was tested in an animal model system following either irradiation or administration of the chemotherapeutic agent cisplatin. These experiments demonstrated the unexpected platelet stimulatory effect.
  • [0096]
    More specifically, saline or neutral soluble glucan prepared as described in Example 1 was administered to groups of 10 mice as a single IV bolus 20 hours prior to radiation exposure. Mice were bilaterally exposed to a total-body irradiation of 7.5-Gy. Fourteen days after irradiation the mice were sacrificed and whole blood samples were analyzed for peripheral blood counts. As shown in FIG. 7, the platelet cell count from neutral soluble glucan-treated mice was increased nearly 3-fold relative to saline-treated control levels.
  • [0097]
    In addition to tests on irradiated mice, cisplatin-treated mice were also tested for the effect of the neutral soluble glucan on platelet hematopoiesis. Balbic mice were injected intravenously with cisplatin at a dose of 9.3 mg/kg through the tail vein one hour before injecting either saline or the neutral soluble glucan, prepared as described in Example 1, intramuscularly in a single dose of 0 (saline) or 2 mg/kg on Day 0. Platelet counts were determined before treatment (Day 0) and at 2, 4, 6, 8, and 10 days post-treatment. The results of this experiment are shown in FIG. 8. Each data point represents the mean and standard error of platelet counts from five mice. The statistically significant differences (p<0.05) between the saline and neutral soluble glucan (2 mg/kg) are noted.
  • [0098]
    Biolocical DePosit
  • [0099]
    [0099]Saccharomyces cerevisiae strain R4 Ad was deposited on Aug. 20, 1992 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md., under the terms of the Budapest Treaty. The strain has been assigned ATCC accession number 74181. Upon issuance of a patent, this deposit will be irrevocable.
  • [0100]
    Equivalents
  • [0101]
    Those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, many equivalents to the specific materials and components described herein. Such equivalents are intended to be encompassed in the scope of the following claims:

Claims (28)

  1. 1. A neutral, aqueous soluble β-glucan preparation which enhances host defense mechanisms to infection and does not induce an inflammatory response.
  2. 2. A neutral, aqueous soluble β-glucan preparation of claim 1 in which the host is a human.
  3. 3. A neutral, aqueous soluble β-glucan preparation of claim 1 which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with a human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained following an otherwise identical incubation with a buffered solution lacking the β-glucan component.
  4. 4. A neutral, aqueous soluble β-glucan preparation of claim 1 which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with an endotoxin-stimulated human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained with endotoxin stimulation alone.
  5. 5. A β-glucan preparation of claim 4 in which the human peripheral blood mononuclear cells are stimulated with Escherichia coli lipopolysaccharide endotoxin at a concentration of about 1 ng/ml.
  6. 6. A neutral, aqueous soluble β-glucan preparation consisting essentially of a molecularspecies which migrates as a single peak when analyzed by gel permeation chromatography, the molecular species being characterized by a triple helical conformation.
  7. 7. A neutral, aguecus soluble β-glucan of claim 6 wherein the molecular species binds specifically to the β-glucan receptor of human monocytes.
  8. 8. A neutral, agueous soluble β-glucan having a triple helical conformation which when mixed at a concentration of 1 mg/ml with aniline blue forms a fluorescent complex in 25 mM NaOE and which loses about 50% of its 25 mM NaOH fluorescence in 150 mM NaOH.
  9. 9. A method for producing a neutral, aqueous soluble β-glucan preparation, comprising:
    a) treating a suspension of insoluble β-glucan with an organic acid under conditions sufficient to dissolve the organic acid-soluble portion of the β-glucan;
    b) treating the organic acid-soluble β-glucan with alkali under conditions sufficient to denature the native conformation of the soluble β-glucan;
    c) neutralizing the denatured soluble β-glucan under conditions sufficient to re-anneal the soluble β-glucan; and
    d) purifying the re-annealed soluble β-glucan to obtain a neutrals aqueous soluble β-glucan having a triple helical conformation which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with an endotoxin stimulated human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained with endotoxin stimulation alone.
  10. 10. A method of claim 9 wherein the insoluble β-glucan is a whole glucan particle.
  11. 11. A method of claim 9 wherein step a) is performed at a pH of from about 1 to about 5 and a temperature of from about 20 to about 100° C.
  12. 12. A method of claim 9 wherein the organic acid is acetic acid or formic acid.
  13. 13. The method of claim 9 wherein step (b) is performed at a pH of from about 7 to about 14 and a temperature of from about 40 to about 121° C.
  14. 14. The method of claim 9 further comprising the step of purifying the denatured β-glucan prior to step (c) to remove insoluble β-glucans and aggregated soluble β-glucans therefrom.
  15. 15. The method of claim 9 wherein the purification step is performed using 1,000 to 100,000 dalton nominal molecular weight cut-off ultrafilters.
  16. 16. The method of claim 9 wherein step (c) is performed at a pH of about 3.5 to 11.0 and at a temperature of from about 50 to 70° C.
  17. 17. The method of claim 9 wherein the step (d) is performed using a 30,000 to 70,000 nominal molecular weight cut-off ultrafilter and a 100,000 to 500,000,nominal molecular weight cut-off ultrafilter.
  18. 18. A neutral, aqueous soluble β-glucan produced by the method of claim 9.
  19. 19. A method for preventing infection in a mammal that is at risk for infection, the method comprising parenterally administering to the mammal a neutral, aqueous soluble β-glucan which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with a human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained following an otherwise identical incubation with a buffered solution lacking the β-glucan component.
  20. 20. A method of claim 19 wherein the mammal is at risk for infection as a result of an invasive surgical procedure.
  21. 21. A method for stimulating repair and healing of a wound site on a mammal comprising administering to the wound site, an effective amount of a neutral, aqueous soluble β-glucan which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with a human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained following an otherwise identical incubation with a buffered solution lacking the β-glucan component.
  22. 22. A method of claim 21 wherein the β-glucan is topically administered to the wound site or is injected into the wound site.
  23. 23. A method for stimulating platelet proliferation, comprising administering to a mammal a composition comprising a neutral, aqueous soluble β-glucan in a physiologically acceptable vehicle, the neutral, aqueous soluble β-glucan being prepared by:
    a) treating a suspension of insoluble, β-glucan with an organic acid under conditions sufficient to dissolve the organic acid-soluble portion of the β-glucan;
    b) treating the organic acid-soluble β-glucan with alkali under conditions sufficient to denature the native conformation of the soluble β-glucan;
    c) neutralizing the denatured soluble β-glucan under conditions sufficient to re-anneal the soluble β-glucan; and
    d) purifying the re-annealed soluble β-glucan to obtain a neutral, aqueous soluble β-glucan having a triple helical conformation which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with an endotoxin stimulated human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained with endotoxin stimulation alone.
  24. 24. A pharmaceutical composition comprising a neutral, aqueous soluble β-glucan preparation which enhances host defense mechanisms to infection and does not induce an inflammatory response, the neutral, aqueous soluble β-glucan preparation being solubilized in a pharmaceutically acceptable carrier.
  25. 25. A pharmaceutical composition of claim 24 which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with a human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factors synthesis over levels obtained following an otherwise identical incubation with a pharmaceutically acceptable carrier lacking the β-glucan component.
  26. 26. A method for treating infection in a mammal that is at risk for infection, the method comprising parenterally administering to the mammal a neutral, aqueous soluble β-glucan which, when incubated for greater than 3 hours at a concentration of about 1 μg/ml with a human peripheral blood mononuclear cell culture of about 5×106 cells/ml, results in a less than 2-fold increase in interleukin-1β and tumor necrosis factor-α synthesis over levels obtained following an otherwise identical incubation with a buffered solution lacking the β-glucan component.
  27. 27. A method of claim 26 wherein the mammal is at risk for infection as a result of an invasive surgical procedure.
  28. 28. The method of claim 16 wherein step (c) is performed at a ph of about 6.0 to 8.0.
US09841179 1992-08-21 2001-04-24 Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same Abandoned US20020032170A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US07934015 US5622939A (en) 1992-08-21 1992-08-21 Glucan preparation
US08373251 US5783569A (en) 1992-08-21 1993-08-20 Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same
US08469233 US5817643A (en) 1992-08-21 1995-06-06 Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
US16645498 true 1998-10-05 1998-10-05
US32651399 true 1999-06-04 1999-06-04
US09841179 US20020032170A1 (en) 1992-08-21 2001-04-24 Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09841179 US20020032170A1 (en) 1992-08-21 2001-04-24 Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same
US10719432 US20040116380A1 (en) 1992-08-21 2003-11-21 Underivatized, aqueous soluble beta(1-3) glucan, composition and method of making same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US32651399 Continuation 1999-06-04 1999-06-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10719432 Continuation US20040116380A1 (en) 1992-08-21 2003-11-21 Underivatized, aqueous soluble beta(1-3) glucan, composition and method of making same

Publications (1)

Publication Number Publication Date
US20020032170A1 true true US20020032170A1 (en) 2002-03-14

Family

ID=25464815

Family Applications (5)

Application Number Title Priority Date Filing Date
US07934015 Expired - Lifetime US5622939A (en) 1992-08-21 1992-08-21 Glucan preparation
US08373251 Expired - Lifetime US5783569A (en) 1992-08-21 1993-08-20 Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same
US08469233 Expired - Lifetime US5817643A (en) 1992-08-21 1995-06-06 Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
US09841179 Abandoned US20020032170A1 (en) 1992-08-21 2001-04-24 Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same
US10719432 Abandoned US20040116380A1 (en) 1992-08-21 2003-11-21 Underivatized, aqueous soluble beta(1-3) glucan, composition and method of making same

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US07934015 Expired - Lifetime US5622939A (en) 1992-08-21 1992-08-21 Glucan preparation
US08373251 Expired - Lifetime US5783569A (en) 1992-08-21 1993-08-20 Uses for underivatized, aqueous soluble β(1-3) glucan and compositions comprising same
US08469233 Expired - Lifetime US5817643A (en) 1992-08-21 1995-06-06 Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10719432 Abandoned US20040116380A1 (en) 1992-08-21 2003-11-21 Underivatized, aqueous soluble beta(1-3) glucan, composition and method of making same

Country Status (6)

Country Link
US (5) US5622939A (en)
EP (1) EP0655921B1 (en)
JP (3) JPH06107702A (en)
DE (2) DE69331324D1 (en)
FI (1) FI950770A (en)
WO (1) WO1994004163A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281781A1 (en) * 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods
US20060083718A1 (en) * 2004-06-16 2006-04-20 University Of Massachusetts Novel therapy for lysosomal enzyme deficiencies
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2010042991A1 (en) * 2008-10-15 2010-04-22 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
US20100190872A1 (en) * 2005-05-05 2010-07-29 Sensient Flavors Inc. Production of beta-glucans and mannans
US9610303B2 (en) 2006-06-15 2017-04-04 Biothera, Inc. Glucan preparations
WO2017180760A1 (en) * 2016-04-12 2017-10-19 Kemin Industries, Inc. Methods to facilitate the solubilization of beta-1,3-glucan and enhance immune function and other related uses

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5718694A (en) * 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
CA2189010C (en) * 1994-04-29 2010-07-13 Rolf Engstad Enzyme treatment of glucans
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
WO1996028476A1 (en) 1995-03-13 1996-09-19 Novogen Research Ltd. Process for glucan preparation and therapeutic uses of glucan
GB2331014C (en) * 1995-03-13 2005-06-21 Novogen Res Pty Ltd Therapeutic uses of glucan
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US6413715B2 (en) 1997-01-31 2002-07-02 The Collaborative Group β(1-3)-glucan diagnostic assays
US6084092A (en) * 1997-01-31 2000-07-04 The Collaborative Group, Ltd. β(1-3)-glucan diagnostic assays
US6090938A (en) * 1996-05-01 2000-07-18 Collaborative Group, Ltd. Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan
US6110692A (en) 1996-05-01 2000-08-29 The Collaborative Group, Ltd. Receptor for underivatized aqueous soluble β(1-3)-glucan
EP0849585A3 (en) * 1996-12-18 1998-09-02 Kabushiki Kaisha Egawa A microbe and cell function control device, a method of controlling the same, and a microbial ecology detector device
GB9714102D0 (en) * 1997-07-04 1997-09-10 Ciba Geigy Ag Compounds
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
KR100680014B1 (en) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
US5980918A (en) * 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
WO1999031504A1 (en) * 1997-12-12 1999-06-24 Alpha-Beta Technology, Inc. ACTIVATION OF TRANSCRIPTION FACTOR COMPLEX BY β(1-3) GLUCAN
WO1999067418A1 (en) * 1998-06-25 1999-12-29 The Collaborative Group, Ltd. Beta(1,3)-glucan microfibril assembly assay
US7022685B2 (en) 1998-09-25 2006-04-04 Biopolymer Engineering, Inc. Very high molecular weight β-glucans
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6210686B1 (en) 1998-12-18 2001-04-03 Beth Israel Deaconess Medical Center Dietary supplement and method for lowering risk of heart disease
US6143883A (en) * 1998-12-31 2000-11-07 Marlyn Nutraceuticals, Inc. Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
WO2000042994A3 (en) * 1999-01-21 2003-08-28 Sanna M Goyert Inhibition of bacterial dissemination
DE19911055A1 (en) * 1999-03-12 2000-09-21 Cognis Deutschland Gmbh Use of surfactants mixtures
CA2366897C (en) * 1999-04-06 2009-11-17 Andrew B. Onderdonk Immunomodulatory compositions and methods of use thereof
US6369648B1 (en) 1999-04-21 2002-04-09 Hughes Electronics Corporation Linear traveling wave tube amplifier utilizing input drive limiter for optimization
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US6713459B1 (en) 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
JP2001354570A (en) * 2000-06-15 2001-12-25 Ichimaru Pharcos Co Ltd Immunoactivating agent and cosmetic using the same
US20040054166A1 (en) 2000-08-03 2004-03-18 Martin Sauter Isolation of glucan particles and uses thereof
EP1357919B1 (en) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP2009528267A (en) * 2006-01-17 2009-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Glucan to enhance the therapeutic
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
JP4499979B2 (en) * 2001-05-21 2010-07-14 コンビ株式会社 Pathogen infection composition for inhibiting
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
EP1451336A2 (en) * 2001-09-03 2004-09-01 Medimush APS Production of fungal extracellular immune stimulating compounds
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
EP1545208A4 (en) 2002-08-13 2006-04-12 Biopolymer Engineering Inc Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP2181711A1 (en) 2002-09-04 2010-05-05 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
KR100457270B1 (en) * 2003-03-18 2004-11-16 주식회사 엔바이오테크놀러지 Composition comprising soluble glucan oligomer from Saccharomyces cerevisiae IS2 for immune activation or prevention and treatment of cancer and the preparation method thereof
US20060121131A1 (en) * 2003-05-02 2006-06-08 Ceapro Inc. Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan
EP1620469B1 (en) 2003-05-02 2013-04-10 Ceapro Inc. Improved extraction and purification method for cereal beta (1-3) beta (1-4) glucan
KR100419191B1 (en) * 2003-06-23 2004-02-05 주식회사 엔바이오테크놀러지 Composition comprising soluble glucan oligomer from Saccharomyces cerevisiae IS2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (TGEV) virus
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
KR100485056B1 (en) * 2004-01-19 2005-04-14 (주)네추럴에프앤피 Anti h1n2 type viral composition comprising soluble glucan oligomer of saccharomyces cerevisiae
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US7514085B2 (en) * 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
US20060079481A1 (en) * 2004-10-08 2006-04-13 Rolf Engstad Method of treating/preventing mucositis
US20060084629A1 (en) * 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
US20090092641A1 (en) * 2004-10-18 2009-04-09 Progressive Bioactivities, Inc. Uses of natural immunobiotic extract
WO2006067147A1 (en) * 2004-12-23 2006-06-29 Dsm Ip Assets B.V. Process to improve activity of mannoprotein as wine stabiliser
EP1828372A1 (en) * 2004-12-23 2007-09-05 DSMIP Assets B.V. New mannoprotein with full solubility in wine and its application in the stabilisation of wine
EP1714675A1 (en) * 2005-04-21 2006-10-25 Desol BV Method for increasing the speed of wound healing of injured animals
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
US9072776B2 (en) 2005-06-15 2015-07-07 Glycanova As Anti-cancer combination treatment and kit-of-parts
EP1896601A1 (en) * 2005-06-15 2008-03-12 Medimush A/S Bioactive agents produced by submerged cultivation of a basidiomycete cell
US7695246B2 (en) * 2006-01-31 2010-04-13 United Technologies Corporation Microcircuits for small engines
JP4802821B2 (en) * 2006-03-31 2011-10-26 ダイソー株式会社 Method for producing purified β-D- glucan
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
CN101626773B (en) * 2006-11-02 2013-04-17 奥力有限公司 Agent for promoting healing of living body
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP6082174B2 (en) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Immunomodulatory compositions and methods of use thereof
JP4979467B2 (en) * 2006-12-05 2012-07-18 尚仁 大野 Anti-β- glucan antibody measurement method and the measurement kit
KR101665216B1 (en) * 2007-05-08 2016-10-11 바이오테라, 인크. Particulate-soluble glucan preparation
KR20100077175A (en) * 2007-09-27 2010-07-07 바이오폴리머 엔지니어링 인코포레이티드 β-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING
JP2011503161A (en) * 2007-11-13 2011-01-27 バイオテック・ファルマコン・アーエスアーBiotec Pharmacon Asa Method of treating or preventing inflammatory diseases of the gut
US20110065911A1 (en) * 2008-02-19 2011-03-17 Novogen Research Pty Ltd Method for producing a bioactive glucan product substantially free of endotoxin contamination
US20120003178A1 (en) * 2008-02-19 2012-01-05 Novogen Research Pty Ltd Evaluating the therapeutic potential of a glucan
CN101965367B (en) * 2008-03-11 2013-07-24 未来纤维技术有限公司 Modalmetric fibre sensor
FI20080665A0 (en) 2008-12-18 2008-12-18 Glykos Finland Oy The natural types of sakkaridikoostumukset
CN101434974B (en) 2008-12-18 2011-11-09 山东大学 Method for preparing soluble beta-1,3-oligoglucoside by using yeast
US20120015903A1 (en) * 2010-07-16 2012-01-19 Fu Jen Catholic University PHARMACEUTICAL COMPOSITION FOR INHIBITING INCREASE OF IgA
WO2012167061A1 (en) * 2011-06-03 2012-12-06 Biothera, Inc. OPSONIZED β-GLUCAN PREPARATIONS AND METHODS
WO2013065732A1 (en) * 2011-10-31 2013-05-10 興人ライフサイエンス株式会社 Effective use of yeast and yeast extract residue
US20160184343A1 (en) 2014-04-14 2016-06-30 Uab "Biocentras" Therapeutical beta-glucan composition, modulating human immune system and initiating the breakdown of cancerous cells
US20160256480A1 (en) * 2015-03-03 2016-09-08 Wintley PHIPPS Therapeutic composition for wound healing
CN105153440B (en) * 2015-07-10 2018-01-16 南雄阳普医疗科技有限公司 A method for the preparation of dextran microspheres gel
JP6293187B2 (en) * 2016-03-22 2018-03-14 株式会社アウレオ Compositions for hematopoietic function enhancement, and compositions for the prevention and / or amelioration of anemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide, its preparation, and oncostatic drugs containing it as an effective component
JPS5571701A (en) * 1978-11-24 1980-05-30 Sankyo Co Ltd Hydrolyzate polysaccharide, its preparation, and immunoregulator containing hydrolyzate polysaccharide as active ingredient
JPS5676401A (en) * 1979-11-27 1981-06-24 Hiroyoshi Hidaka Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
GB2076418A (en) * 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
JPH026761B2 (en) * 1982-09-09 1990-02-13 Tosoh Corp
JPS6356881B2 (en) * 1983-05-17 1988-11-09 Nippon Kinoko Kenkyusho
US4707471A (en) * 1983-12-19 1987-11-17 Medicarb Ab Water-soluble aminated β-1,3-bound D-glucan and composition containing same
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
DE69030880D1 (en) * 1989-09-08 1997-07-10 Alpha Beta Technology A composition for stimulating the immune system
EP0490995A1 (en) * 1989-09-08 1992-06-24 Alpha Beta Technology Method for producing soluble glucans
JP2911554B2 (en) * 1990-06-25 1999-06-23 台糖株式会社 Anti-viral agents
WO1992013896A1 (en) * 1991-02-01 1992-08-20 Bioglucans, L.P. Soluble glucans
EP0654045A4 (en) * 1992-08-05 1996-03-20 Bioglucans L P Improved method for preparing soluble glucans.
EP0654047A1 (en) * 1992-08-10 1995-05-24 Consiglio Nazionale Delle Ricerche Glucans with immunostimulant activity
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060083718A1 (en) * 2004-06-16 2006-04-20 University Of Massachusetts Novel therapy for lysosomal enzyme deficiencies
US9682135B2 (en) 2004-06-16 2017-06-20 University Of Massachusetts Drug delivery product and methods
US8637045B2 (en) 2004-06-16 2014-01-28 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
US8580275B2 (en) 2004-06-16 2013-11-12 University Of Massachusetts Drug delivery product and methods
US8007814B2 (en) 2004-06-16 2011-08-30 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
US20100221357A1 (en) * 2004-06-16 2010-09-02 University Of Massachusetts Drug delivery product and methods
US20050281781A1 (en) * 2004-06-16 2005-12-22 Ostroff Gary R Drug delivery product and methods
US20100190872A1 (en) * 2005-05-05 2010-07-29 Sensient Flavors Inc. Production of beta-glucans and mannans
US8753668B2 (en) 2005-05-05 2014-06-17 Sensient Flavors Llc Production of beta-glucans and mannans
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US9610303B2 (en) 2006-06-15 2017-04-04 Biothera, Inc. Glucan preparations
WO2008027580A3 (en) * 2006-09-01 2008-11-13 Univ Louisville Res Found PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
US8389485B2 (en) 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2010042991A1 (en) * 2008-10-15 2010-04-22 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
US20110301118A1 (en) * 2008-10-15 2011-12-08 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
WO2017180760A1 (en) * 2016-04-12 2017-10-19 Kemin Industries, Inc. Methods to facilitate the solubilization of beta-1,3-glucan and enhance immune function and other related uses

Also Published As

Publication number Publication date Type
DE69331324T2 (en) 2002-08-22 grant
DE69331324D1 (en) 2002-01-24 grant
FI950770A (en) 1995-02-20 application
FI950770D0 (en) grant
US5783569A (en) 1998-07-21 grant
FI950770A0 (en) 1995-02-20 application
US5622939A (en) 1997-04-22 grant
US5817643A (en) 1998-10-06 grant
WO1994004163A1 (en) 1994-03-03 application
JP2005264167A (en) 2005-09-29 application
US20040116380A1 (en) 2004-06-17 application
JPH08500623A (en) 1996-01-23 application
EP0655921A1 (en) 1995-06-07 application
EP0655921B1 (en) 2001-12-12 grant
JPH06107702A (en) 1994-04-19 application

Similar Documents

Publication Publication Date Title
Leung et al. The isolation and characterization of an immunomodulatory and anti-tumor polysaccharide preparation from Flammulina velutipes
Sasaki et al. Dependence on chain length of antitumor activity of (1→ 3)-β-D-glucan from Alcaligenes faecalis var. myxogenes, IFO 13140, and its acid-degraded products
Kincade et al. Growth of B-lymphocytes clones in semisolid culture is mitogen dependent.
Necas et al. Carrageenan: a review.
US5567685A (en) Water-Soluble polyene conjugate
Nishimura et al. Bioactive chitin derivatives. Activation of mouse-peritoneal macrophages by O-(carboxymethyl) chitins
JANN et al. Microbial polysaccharides
Haijin et al. A κ-carrageenan derived oligosaccharide prepared by enzymatic degradation containing anti-tumor activity
Otterlei et al. Characterization of binding and TNF-α-inducing ability of chitosans on monocytes: the involvement of CD14
US7115588B2 (en) Methods for treating a breach or puncture in a blood vessel
Nishimura et al. Macrophage activation with multi‐porous beads prepared from partially deacetylated chitin
Domard et al. Chitosan: structure-properties relationship and biomedical applications
US5773425A (en) Antineoplastic uses of aloe products
US5872109A (en) Anti-inflammatory agent
US5051408A (en) Inulin compositions in gamma polymorphic form
US5409703A (en) Dried hydrogel from hydrophilic-hygroscopic polymer
Inngjerdingen et al. Bioactive pectic polysaccharides from Glinus oppositifolius (L.) Aug. DC., a Malian medicinal plant, isolation and partial characterization
US5118673A (en) Uses of aloe products
Williams et al. Glucan-based macrophage stimulators
US4818752A (en) Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases
Garner et al. Secretion of TNF‐α by alveolar macrophages in response to Candida albicans mannan
EP0466315A2 (en) Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US4900722A (en) Methods and compositions for prophylactic and therapeutic treatment of infections
Suzuki et al. Protecting effect of chitin and chitosan on experimentally induced murine candidiasis
Onderdonk et al. Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo.